WNT3 (Wnt Family Member 3) encodes a key signaling protein involved in embryonic development, tissue patterning, and cellular homeostasis. As a founding member of the Wnt family, WNT3 plays critical roles in neural development, synaptic plasticity, and dopaminergic neuron survival—processes directly relevant to neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD) [1]. This gene is located on chromosome 12q13.12 and encodes a secreted glycoprotein that signals through Frizzled receptors to activate downstream pathways including canonical Wnt/β-catenin signaling and planar cell polarity (PCP) pathways [2].
The WNT3 gene has attracted significant research attention in the neurodegener field due to its crucial roles in neurodevelopment, synaptic function, and neural repair. Dysregulation of Wnt signaling has been implicated in the pathogenesis of multiple neurodegenerative disorders, making WNT3 a potential therapeutic target. This comprehensive review covers WNT3's normal function, molecular mechanisms, disease associations, expression patterns, and therapeutic implications.
| Property | Value |
|---|---|
| Gene Symbol | WNT3 |
| Gene Name | Wnt Family Member 3 |
| Chromosomal Location | 12q13.12 |
| NCBI Gene ID | 7476 |
| OMIM | 165330 |
| UniProt | P56703 |
| Ensembl | ENSG00000108379 |
| Protein Class | Signaling molecule, developmental protein |
| Expression | Brain, spinal cord, peripheral tissues |
WNT3 is a member of the Wnt family of secreted cysteine-rich glycoproteins. The WNT3 protein undergoes extensive post-translational modifications including palmitoylation at a conserved cysteine residue, which is essential for its secretion and signaling activity [1:1]. The mature WNT3 protein is approximately 350 amino acids in length and contains a conserved Wnt-1 domain responsible for receptor binding and downstream signaling.
WNT3 functions as a ligand for Frizzled (FZD) family receptors, of which there are 10 members in humans (FZD1-10). Binding of WNT3 to FZD receptors initiates signaling through multiple downstream pathways:
Canonical Wnt/β-catenin pathway: WNT3 binding to FZD receptors activates Dishevelled (DVL), which inhibits the β-catenin destruction complex. This leads to β-catenin accumulation and translocation to the nucleus, where it co-activates TCF/LEF transcription factors to drive expression of target genes including AXIN2, MYC, and CCND1 [2:1].
Planar cell polarity (PCP) pathway: In a β-catenin-independent manner, WNT3 can activate PCP signaling through FZD and DVL, leading to activation of small GTPases (RhoA, Rac1) and downstream effectors (JNK, ROCK) that regulate cytoskeletal dynamics and cell polarity [@noncanonical2020].
Wnt/Ca²⁺ pathway: WNT3 can also activate intracellular calcium signaling through FZD receptors, leading to activation of CaMKII and PKC, which modulate synaptic plasticity and neuronal function.
WNT3 plays essential roles in multiple developmental and physiological processes:
During embryonic development, WNT3 is expressed in the dorsal neural tube and plays crucial roles in patterning the anterior-posterior axis of the nervous system [3]. WNT3 signaling regulates the specification of neural progenitor cells, promotes neuronal differentiation, and controls axonal guidance. In the developing midbrain, WNT3 is involved in the specification and survival of dopaminergic neurons, which are particularly vulnerable in Parkinson's disease [4].
In mature neurons, WNT3 continues to play important roles in synaptic function. WNT3 signaling at synapses regulates the formation and maintenance of dendritic spines, the sites of excitatory synaptic transmission [5]. WNT3 modulates long-term potentiation (LTP) and long-term depression (LTD), two forms of synaptic plasticity that underlie learning and memory. The protein is localized to both pre-synaptic and post-synaptic compartments, where it acts in an autocrine and/or paracrine manner.
WNT3 signaling promotes neurogenesis in the adult brain, particularly in the hippocampus [5:1]. The Wnt/β-catenin pathway activates transcription of genes involved in neural stem cell proliferation and neuronal differentiation. This function has implications for understanding and potentially treating neurodegenerative diseases, as adult neurogenesis may contribute to brain repair.
WNT3 has anti-apoptotic properties that protect neurons from various toxic insults. The canonical Wnt/β-catenin pathway activates expression of anti-apoptotic proteins including Bcl-2 and survivin, while also inhibiting pro-apoptotic factors such as BAD and caspase-3 activation [4:1].
WNT3 signaling is dysregulated in Alzheimer's disease, contributing to several pathological features. Amyloid-beta (Aβ) oligomers, the toxic species in AD, suppress Wnt/β-catenin signaling in neurons, creating a permissive environment for synaptic dysfunction and tau pathology [6]. The canonical Wnt pathway normally protects against Aβ-induced toxicity, so its impairment in AD represents a double hit—both loss of neuroprotection and gain of pathogenic signaling.
Tau pathology, characterized by hyperphosphorylated tau forming neurofibrillary tangles, also intersects with Wnt signaling. GSK3β, a key kinase that phosphorylates tau, is inhibited by Wnt/β-catenin signaling. Thus, loss of WNT3 signaling leads to increased GSK3β activity, promoting tau hyperphosphorylation [2:2].
The synaptic deficits in AD are strongly linked to Wnt signaling impairment. WNT3 is essential for maintaining synaptic structure and function through regulation of synaptic proteins including PSD95, NMDA receptor subunits, and AMPA receptor trafficking [5:2]. Loss of WNT3 signaling in AD contributes to the well-documented synaptic loss that correlates with cognitive decline.
Neuroinflammation is a major contributor to AD pathogenesis. WNT3 signaling has anti-inflammatory effects in the brain, and its dysfunction may exacerbate neuroinflammation [2:3]. Microglia from AD patients show impaired Wnt signaling, which may contribute to their pro-inflammatory phenotype. Therapeutic approaches that restore Wnt signaling may thus have dual benefits for both neuronal survival and inflammation control.
Given the central role of WNT3 signaling loss in AD, multiple therapeutic strategies are being explored:
Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). WNT3 plays a critical role in the development, maintenance, and survival of these neurons [4:2]. During development, WNT3 signaling is essential for the specification and differentiation of dopaminergic progenitors. In adulthood, WNT3 continues to protect dopaminergic neurons from various toxic insults.
Multiple studies have shown that WNT3 expression is reduced in the PD brain, particularly in regions affected by neurodegeneration [6:1]. This loss of WNT3 signaling may contribute to the selective vulnerability of dopaminergic neurons, which have high metabolic demands and are particularly dependent on Wnt-mediated neuroprotection.
Alpha-synuclein (αSyn) aggregation, the hallmark pathology of PD, interacts with Wnt signaling. αSyn accumulation disrupts Wnt/β-catenin signaling in neurons, creating a vicious cycle where neurodegeneration impairs neuroprotective signaling, which in turn accelerates αSyn pathology [6:2]. Restoring Wnt signaling may therefore have therapeutic benefits by both protecting neurons and reducing αSyn toxicity.
Mitochondrial dysfunction is a central feature of PD pathogenesis. WNT3 signaling regulates mitochondrial biogenesis through activation of PGC-1α, the master regulator of mitochondrial function [4:3]. Loss of WNT3 signaling therefore contributes to the mitochondrial deficits observed in PD, including reduced ATP production, increased reactive oxygen species (ROS), and impaired mitophagy.
Similar to AD, neuroinflammation plays a significant role in PD pathogenesis. WNT3 signaling has anti-inflammatory effects in the brain, and its impairment may exacerbate microglial activation and neuroinflammation [4:4]. Therapeutic targeting of Wnt signaling may therefore provide benefits by modulating neuroinflammation.
Multiple approaches to restore WNT3 signaling in PD are under investigation:
WNT3 exhibits tissue-specific and developmental stage-specific expression:
WNT3 is also expressed in various peripheral tissues including:
Tetra-amelia syndrome: Autosomal recessive mutations in WNT3 cause tetra-amelia syndrome, characterized by limb malformations and other developmental defects [7]. This demonstrates the critical importance of WNT3 in embryonic development.
Neural tube defects: WNT3 mutations are associated with neural tube defects including spina bifida, reflecting its role in neural tube patterning.
Alzheimer's disease: WNT3 signaling is impaired in AD brains. Reduced WNT3 expression correlates with disease severity, and restoration of Wnt signaling is protective in animal models [6:3].
Parkinson's disease: WNT3 is reduced in PD brains. Wnt pathway activation protects dopaminergic neurons in models of PD, and this pathway is considered a promising therapeutic target [4:5].
Amyotrophic lateral sclerosis (ALS): Wnt signaling is dysregulated in ALS, and WNT3 may play protective roles in motor neurons [2:4].
Frontotemporal dementia (FTD): Wnt pathway dysfunction has been reported in FTD, though the specific role of WNT3 is less characterized.
WNT3 can function as an oncogene when dysregulated:
This dual role—as a tumor suppressor in adulthood but an oncogene when dysregulated—presents challenges for therapeutic targeting.
Wnt3 knockout mice are embryonic lethal, demonstrating the essential role of this gene in development. Studies using conditional knockouts have shown that loss of Wnt3 in the brain leads to defects in neurogenesis, hippocampal development, and synaptic function [5:3].
Transgenic mice overexpressing WNT3 have been generated for study purposes. These mice show enhanced neurogenesis and improved cognitive function, supporting the therapeutic potential of Wnt pathway activation.
WNT3 and Wnt signaling more broadly serve as important research targets for:
WNT3 levels in cerebrospinal fluid (CSF) and blood are being investigated as potential biomarkers for neurodegenerative diseases. Changes in WNT3 expression may reflect disease progression and treatment response.
Multiple clinical trials are targeting Wnt signaling in neurodegenerative diseases:
Therapeutic targeting of WNT3 presents challenges:
Nusse R, Clevers H. Wnt proteins: from development to regeneration. Cell. 2023. ↩︎ ↩︎
Liu IA, et al. Wnt signaling in neurodegenerative diseases. Ageing Research Reviews. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Sarra B, et al. Canonical and non-canonical Wnt signaling in neural stem cells. Stem Cells. 2018. ↩︎
Marchetti B, et al. Wnt/β-catenin pathway in Parkinson's disease: focus on glial cell line-derived neurotrophic factor. Journal of Parkinson's Disease. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Inestrosa NC, et al. Wnt signaling function in Alzheimer's disease: from neurogenesis to synaptic plasticity. Molecular Neurobiology. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Zhang L, et al. Wnt signaling in Parkinson's disease. Ageing Research Reviews. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Arber C, et al. Wnt signaling in development and disease. Developmental Biology. 2018. ↩︎